Campbell Bradley L's Form 4 filing
Amicus Therapeutics, Inc. (FOLD) · filed Nov 26, 2025
- Accession no.
- 0001193125-25-301018
- Filed
- Nov 26, 2025
- Trade date
- Nov 24, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $146.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Campbell Bradley LCIK 0001400971 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 24, 2025 | Common Stock | MOption exerciseAcquired | +14,587 | $9.03 | +$131,720.61 | 1,151,869 | Direct | |
| Nov 24, 2025 | Common Stock | SSaleDisposed | −14,587 | $10.04F1 | −$146,453.48 | 1,137,282 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 24, 2025 | Common Stock | MOption exerciseDisposed | −14,587 | $0.00 | $0 | 85,013 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.00 to $10.17 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024.